What is your preferred first-line treatment for metastatic gastric adenocarcinoma that is PD-L1 CPS >= 10 and also HER2+?  

At this point, the answer is (pretty) clear. KEYNOTE-811 demonstrated an improvement in response rates for the addition of pembrolizumab to trastuzumab/chemotherapy (75% vs. 52%, p=0.00006) in its first planned interim analysis. While PFS and OS data are immature, this result was sufficient to obtai...

We all need to work together and bring the KN-811 regimen to the neoadjuvant setting for HER2+ve gastroesophageal adenocarcinoma patients. Giving FLOT-4 to HER2+ gastric or GEJ carcinoma patients doesn't make much sense in the post-KN-811 era... but we need data.